Cargando…

Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System

PURPOSE: To assess occlusion success and adverse events associated with the use of a self-expanding device for peripheral artery embolization. METHODS: This prospective, single-arm, feasibility study was conducted using the Caterpillar™ Arterial Embolization Device composed of opposing nitinol fiber...

Descripción completa

Detalles Bibliográficos
Autores principales: Holden, Andrew, Mwipatayi, Bibombe P., Khashram, Manar, Dubenec, Steven, Goh, Gerard S., Settlage, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713177/
https://www.ncbi.nlm.nih.gov/pubmed/36450994
http://dx.doi.org/10.1007/s00270-022-03300-1
_version_ 1784841958755139584
author Holden, Andrew
Mwipatayi, Bibombe P.
Khashram, Manar
Dubenec, Steven
Goh, Gerard S.
Settlage, Richard A.
author_facet Holden, Andrew
Mwipatayi, Bibombe P.
Khashram, Manar
Dubenec, Steven
Goh, Gerard S.
Settlage, Richard A.
author_sort Holden, Andrew
collection PubMed
description PURPOSE: To assess occlusion success and adverse events associated with the use of a self-expanding device for peripheral artery embolization. METHODS: This prospective, single-arm, feasibility study was conducted using the Caterpillar™ Arterial Embolization Device composed of opposing nitinol fibers and a flow-occluding membrane. Twenty patients (24 embolization sites) were treated at four investigational centers in New Zealand and Australia and followed for 30 days. Embolization sites included mesenteric, accessory renal, and iliac arteries and their branches. Primary outcome measures were peri-procedural occlusion confirmed by angiography and freedom from device-related serious adverse events (SAEs) at 30 days. Secondary observations included time to occlusion and assessment of adverse events. RESULTS: Peri-procedural occlusion was 100%, and freedom from a device-related SAE was 94.7% at 30 days. One patient had abdominal bloating that required hospitalization deemed possibly related to the device or procedure. Twenty-two of 24 embolization sites were occluded with one device (91.7%). Mean procedure duration was 11.7 ± 8.6 min (device deployment time: 1.8 ± 1.0 min), and mean fluoroscopy time was 241 ± 290.7 s. All embolization sites occluded during the procedure with 62.5% occluded within three minutes and 91.6% occluded within ten minutes. No devices migrated or required re-embolization. Freedom from device- and procedure-related adverse events was 84.2%. One patient died from aortic rupture during a subsequent adjunctive abdominal aortic endovascular procedure deemed unrelated to the embolization device or procedure. CONCLUSIONS: This first-in-human study of the Caterpillar embolization device achieved peri-procedural occlusion in all patients with a 94.7% freedom from device-related SAE at 30 days. LEVEL OF EVIDENCE: Level 2b—prospective, multicenter, single-arm, first-in-human clinical study. Pre-specified endpoints were analyzed using descriptive statistics.
format Online
Article
Text
id pubmed-9713177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-97131772022-12-01 Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System Holden, Andrew Mwipatayi, Bibombe P. Khashram, Manar Dubenec, Steven Goh, Gerard S. Settlage, Richard A. Cardiovasc Intervent Radiol Clinical Investigation PURPOSE: To assess occlusion success and adverse events associated with the use of a self-expanding device for peripheral artery embolization. METHODS: This prospective, single-arm, feasibility study was conducted using the Caterpillar™ Arterial Embolization Device composed of opposing nitinol fibers and a flow-occluding membrane. Twenty patients (24 embolization sites) were treated at four investigational centers in New Zealand and Australia and followed for 30 days. Embolization sites included mesenteric, accessory renal, and iliac arteries and their branches. Primary outcome measures were peri-procedural occlusion confirmed by angiography and freedom from device-related serious adverse events (SAEs) at 30 days. Secondary observations included time to occlusion and assessment of adverse events. RESULTS: Peri-procedural occlusion was 100%, and freedom from a device-related SAE was 94.7% at 30 days. One patient had abdominal bloating that required hospitalization deemed possibly related to the device or procedure. Twenty-two of 24 embolization sites were occluded with one device (91.7%). Mean procedure duration was 11.7 ± 8.6 min (device deployment time: 1.8 ± 1.0 min), and mean fluoroscopy time was 241 ± 290.7 s. All embolization sites occluded during the procedure with 62.5% occluded within three minutes and 91.6% occluded within ten minutes. No devices migrated or required re-embolization. Freedom from device- and procedure-related adverse events was 84.2%. One patient died from aortic rupture during a subsequent adjunctive abdominal aortic endovascular procedure deemed unrelated to the embolization device or procedure. CONCLUSIONS: This first-in-human study of the Caterpillar embolization device achieved peri-procedural occlusion in all patients with a 94.7% freedom from device-related SAE at 30 days. LEVEL OF EVIDENCE: Level 2b—prospective, multicenter, single-arm, first-in-human clinical study. Pre-specified endpoints were analyzed using descriptive statistics. Springer US 2022-11-30 2023 /pmc/articles/PMC9713177/ /pubmed/36450994 http://dx.doi.org/10.1007/s00270-022-03300-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Investigation
Holden, Andrew
Mwipatayi, Bibombe P.
Khashram, Manar
Dubenec, Steven
Goh, Gerard S.
Settlage, Richard A.
Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System
title Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System
title_full Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System
title_fullStr Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System
title_full_unstemmed Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System
title_short Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System
title_sort results from the first-in-human study of the caterpillar™ arterial embolization system
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713177/
https://www.ncbi.nlm.nih.gov/pubmed/36450994
http://dx.doi.org/10.1007/s00270-022-03300-1
work_keys_str_mv AT holdenandrew resultsfromthefirstinhumanstudyofthecaterpillararterialembolizationsystem
AT mwipatayibibombep resultsfromthefirstinhumanstudyofthecaterpillararterialembolizationsystem
AT khashrammanar resultsfromthefirstinhumanstudyofthecaterpillararterialembolizationsystem
AT dubenecsteven resultsfromthefirstinhumanstudyofthecaterpillararterialembolizationsystem
AT gohgerards resultsfromthefirstinhumanstudyofthecaterpillararterialembolizationsystem
AT settlagericharda resultsfromthefirstinhumanstudyofthecaterpillararterialembolizationsystem